REFERENCES
- Simon R. M. Clinical trials in Cancer. Cancer: Principles & Practice of Oncology. Fifth Edition, V. T. DeVita, S. Hellman, S. A. Rosenberg. Lippincott-Raven Publishers, Philadelphia 1997
- Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R., Phase I II. Clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. JCO 2006; 24: 431–436
- Durie B. G. M., Jacobson J., Barlogie B., Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group Chemotherapy Trials. JCO 2004; 22: 1857–1863
- Barlogie B., Kyle R. A., Anderson K. C., Greipp P. R., Lazarus H. M., Hurd D. D., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US intergroup trial S9321. J Clin Oncol 2006; 24: 929–936
- Facon T., Mary J. Y., Pegourie Attal M., Renaud A., Sadoun A., et al. Dexamethasone based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292–1298
- Richardson P., Anderson K. Thalidomide and Dexamethasone: a new standard of care for initial therapy in Multiple Myeloma. JCO 2006; 24: 334–336
- Natarajan K., Lyman G. H., Ballester O F. Up-Front Therapy for Multiple Myeloma: A Survey of Practice Patterns in the USA. Blood 2005; 106, abstract 5172
- Rajkumar S. V., Jacobus S., Callander N., Fonseca R., Vesole D., Greipp P. A Randomized Phase I II Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood 2006; 108, abstract 799
- Rajkumar S. V., Hayman S. R., Lacy M. Q., Dispenzieri Al., Geyer S. M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4040–4053
- Rajkumar S. V., Jacobus S., Callander N., Fonseca R., Vesole D., Williams M., et al. A randomized Phase I II trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25, abstract 18S
- Bodenheimer T. Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry. N Engl J Med 2000; 342: 1539–1544
- Millar A. W., Lynch K. P. Rethinking clinical trials for cytostatic drugs. Nature Cencer Reviews 2003; 3: 540–545
- Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., et al. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. N Eng J Med 2006; 354: 1021–30
- Attal M., Harousseau J. L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–94
- Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 367: 825–31
- Rajkumar S. V., Hussein M., Catalano J., Jedrzejcak W., Sirkovich S., Olesnyckyj M. A randomized; double-blind, placebo controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. Blood 2006; 108, abstract 795